Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables us to deliver a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. Our team is committed to leveraging ARMMs technology to enable new therapies and address currently unmet medical needs.
Company Details
- Employees
- 9
- Address
- 790 Memorial Dr,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- vesigentx.com
- HQ
- Cambridge, Massachusetts
Vesigen Therapeutics, Inc. Questions
Vesigen Therapeutics, Inc.'s website is vesigentx.com
Vesigen Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/vesigen-therapeutics
Vesigen Therapeutics, Inc. has
9 employees.
View email and phone details for 9
employees at Vesigen Therapeutics, Inc..
Vesigen Therapeutics, Inc.'s industry is
Biotechnology Research
Vesigen Therapeutics, Inc.'s top competitors are
Alnylam Pharmaceuticals,
Kymera Therapeutics,
Connect Biopharma,
Turn Biotechnologies,
Voyager Therapeutics, Inc.,
Entrada Therapeutics,
Tessera Therapeutics,
Editas Medicine,
K2b Therapeutics,
Beam Therapeutics.
Vesigen Therapeutics, Inc.'s categories are Biotechnology Research
